Trials / Completed
CompletedNCT02205099
A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia
A Single-center, Randomized, Double-blind, Flexible-dosage, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- SK Life Science, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-site, randomized, double-blind, placebo-controlled, multiple dose, flexible dosage range, PK and PD study of SKL15508 as monotherapy in subjects with stable schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SKL15508 | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2014-07-31
- Last updated
- 2016-10-13
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02205099. Inclusion in this directory is not an endorsement.